Influence of hormone therapy or C. foetida extract on breast tenderness in postmenopausal women. (4th May 2018)

• Record Type: Journal Article
• Authors: Gao, L.; Zuo, H.; Zheng, T.; Xue, W.; Wang, Y.; Deng, Y.; Sun, A.
• Is Part Of: Climacteric. Volume 21:Number 3(2018)
• Page Start: 292
• Page End: 297
• Publication Date: 2018-05-04
• Subjects: Menopausal women -- menopausal hormone therapy -- Cimicifuga foetida -- breast tenderness; Menopause -- Periodicals; Menopause -- Hormone therapy -- Periodicals; Menopause -- Periodicals; Estrogen Replacement Therapy -- Periodicals; Gynecology -- Periodicals; Societies, Medical -- Periodicals; 612.665
• DOI: 10.1080/13697137.2018.1446929
• Languages: English
• ISSNs: 1369-7137

Abstract

Abstract: Objective: To evaluate the prevalence of breast tenderness in a population treated with menopausal hormone therapy (MHT) or Cimicifuga foetida extract. Methods: A prospective, randomized, controlled trial was conducted. Ninety-six postmenopausal women were randomly assigned to three groups: group A, 1 mg estradiol valerate daily plus 4 mg medroxyprogesterone acetate (MPA), days 19–30; group B, 1 mg estradiol valerate daily plus 100 mg micronized progesterone (MP), days 19–30; group C, 100 mg C. foetida extract daily. Breast tenderness was evaluated daily for 12 months. Results: Seventy-three patients completed the study. Group A had the highest prevalence of breast tenderness, while group C had the lowest. More than 50% of all participants reported no symptoms throughout the period. The participants in group A experienced a sharp increase in breast tenderness after treatment, but decreased after 1 month. No significant decline was found in the duration of pain in group B. The patients in group C reported no remarkable changes after 1 month. Compared to estrogen only, estrogen plus MPA/MP led to a higher incidence of prolonged breast symptoms. Conclusions: Compared to MHT groups, C . foetida extract had the lowest prevalence of breast tenderness. Most participants experienced mild or no symptoms.